$1.01 Billion in Sales Expected for Charles River Laboratories International, Inc. (NYSE:CRL) This Quarter

Equities research analysts predict that Charles River Laboratories International, Inc. (NYSE:CRLGet Rating) will report sales of $1.01 billion for the current quarter, according to Zacks. Six analysts have made estimates for Charles River Laboratories International’s earnings, with the highest sales estimate coming in at $1.03 billion and the lowest estimate coming in at $962.90 million. Charles River Laboratories International reported sales of $914.61 million during the same quarter last year, which would suggest a positive year-over-year growth rate of 10.4%. The firm is expected to announce its next earnings report on Monday, January 1st.

On average, analysts expect that Charles River Laboratories International will report full year sales of $4.03 billion for the current year, with estimates ranging from $4.00 billion to $4.07 billion. For the next financial year, analysts expect that the business will post sales of $4.45 billion, with estimates ranging from $4.35 billion to $4.56 billion. Zacks’ sales calculations are a mean average based on a survey of sell-side analysts that cover Charles River Laboratories International.

Charles River Laboratories International (NYSE:CRLGet Rating) last posted its earnings results on Wednesday, May 4th. The medical research company reported $2.75 earnings per share for the quarter, beating analysts’ consensus estimates of $2.72 by $0.03. Charles River Laboratories International had a return on equity of 21.90% and a net margin of 11.64%. The business had revenue of $913.93 million during the quarter, compared to analyst estimates of $908.64 million. During the same quarter in the previous year, the firm earned $2.53 EPS. The company’s quarterly revenue was up 10.8% compared to the same quarter last year.

Several brokerages have recently commented on CRL. Wells Fargo & Company cut their price objective on Charles River Laboratories International from $390.00 to $325.00 and set an “overweight” rating for the company in a report on Monday, April 25th. Citigroup raised Charles River Laboratories International from a “neutral” rating to a “buy” rating and set a $400.00 price objective for the company in a report on Thursday, February 17th. Stephens began coverage on Charles River Laboratories International in a report on Wednesday, April 6th. They set an “overweight” rating and a $377.00 price objective for the company. Bank of America dropped their target price on Charles River Laboratories International from $445.00 to $400.00 and set a “buy” rating for the company in a research report on Thursday, February 17th. Finally, StockNews.com began coverage on Charles River Laboratories International in a research report on Thursday, March 31st. They issued a “hold” rating for the company. Five analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the company’s stock. According to MarketBeat, Charles River Laboratories International presently has a consensus rating of “Buy” and an average price target of $387.88.

In related news, EVP Joseph W. Laplume sold 396 shares of the company’s stock in a transaction that occurred on Tuesday, February 22nd. The stock was sold at an average price of $290.83, for a total transaction of $115,168.68. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, CEO James C. Foster sold 17,436 shares of the company’s stock in a transaction that occurred on Tuesday, February 22nd. The shares were sold at an average price of $288.67, for a total value of $5,033,250.12. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 38,975 shares of company stock valued at $11,791,146. 1.10% of the stock is owned by corporate insiders.

Institutional investors and hedge funds have recently bought and sold shares of the business. Northwestern Mutual Wealth Management Co. raised its holdings in Charles River Laboratories International by 15.8% in the fourth quarter. Northwestern Mutual Wealth Management Co. now owns 703 shares of the medical research company’s stock worth $265,000 after purchasing an additional 96 shares in the last quarter. Intercontinental Wealth Advisors LLC raised its holdings in Charles River Laboratories International by 67.8% in the fourth quarter. Intercontinental Wealth Advisors LLC now owns 2,446 shares of the medical research company’s stock worth $922,000 after purchasing an additional 988 shares in the last quarter. Brinker Capital Investments LLC raised its holdings in Charles River Laboratories International by 20.3% in the fourth quarter. Brinker Capital Investments LLC now owns 6,172 shares of the medical research company’s stock worth $2,325,000 after purchasing an additional 1,041 shares in the last quarter. Central Bank & Trust Co. bought a new position in shares of Charles River Laboratories International during the fourth quarter valued at $1,932,000. Finally, Tokio Marine Asset Management Co. Ltd. increased its holdings in shares of Charles River Laboratories International by 12.9% during the fourth quarter. Tokio Marine Asset Management Co. Ltd. now owns 685 shares of the medical research company’s stock valued at $258,000 after acquiring an additional 78 shares in the last quarter. Institutional investors and hedge funds own 93.06% of the company’s stock.

Shares of NYSE CRL opened at $241.96 on Monday. Charles River Laboratories International has a 12 month low of $230.62 and a 12 month high of $460.21. The company has a current ratio of 1.34, a quick ratio of 1.04 and a debt-to-equity ratio of 1.02. The firm has a market capitalization of $12.22 billion, a price-to-earnings ratio of 29.47, a PEG ratio of 1.52 and a beta of 1.27. The business has a 50-day moving average of $274.64 and a 200-day moving average of $328.12.

Charles River Laboratories International Company Profile (Get Rating)

Charles River Laboratories International, Inc, a non-clinical contract research organization, provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).

Recommended Stories

Get a free copy of the Zacks research report on Charles River Laboratories International (CRL)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Charles River Laboratories International (NYSE:CRL)

Receive News & Ratings for Charles River Laboratories International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Charles River Laboratories International and related companies with MarketBeat.com's FREE daily email newsletter.